Erratum: Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes (Diabetologia DOI: 10.1007/s00125-010-1767-z);Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes

Diabetologia

Volumn 53, Issue 7, 2010, Pages 1247-1249

  Nolan, J J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Algorithms; Consensus guidelines; Diabetes; Oral pharmacological agents

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ALGORITHM; CARDIOVASCULAR RISK; CONSENSUS DEVELOPMENT; DIABETES CONTROL; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; MEDICAL EXPERT; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; POLYPHARMACY; PRIORITY JOURNAL; PUBLICATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 77955658747     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1816-7     Document Type: Erratum

References (12)

1. Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721.
2. Nathan DM, Buse JB, Davidson MB et al (2009) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30.
3. De Fronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795.
4. Woo V (2009) Important differences: Canadian Diabetes Association (2008) clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:552-553.
5. Schernthaner G, Barnett AH, Betteridge DJ, et al. (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. doi:10.1007/s00125-010-1702-3.
6. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471.
7. Timmers L, Henriques JP, de Kleijn DP et al (2009) Exenatide reduces infarct size and improves cardiac function in a porcinemodel of ischemia and reperfusion injury. J Am Coll Cardiol 53:501-510.
8. Noyan-Ashraf MH, Momen MA, Ban K et al (2009) The GLP1 R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes 58:975-983.
9. Inzucchi SE, McGuire DK (2008) New drugs for the treatment of diabetes: part II-incretin-based therapy and beyond. Circulation 117:574-584.
10. Kahn SE, Haffner DM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443.
11. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777.
12. Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481-489.